Press Releases

OncoSec to Present at NobleCon13

SAN DIEGO, Jan. 26, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its President and Chief Executive Officer, Punit Dhillon, will present at the NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Tuesday, January 31 at 11:30 a.m. EST.

An archived version of the presentation will be available for 90 days on OncoSec's website: http://ir.oncosec.com/events-presentations.

The Noble Financial Capital Markets 13th Annual Investor Conference allows a diverse range of public and private companies to provide formal presentations and request face-to-face meetings with investors and corporate executives. For more information, please visit: https://nobleconference.com/home.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Punit Dhillon
President & Chief Executive Officer
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-noblecon13-300397113.html

SOURCE OncoSec Medical Incorporated